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This work aimed to investigate in vitro the influence of monoolein (MO) on progesterone (PG) transdermal 
delivery and skin retention. Information about the role of MO as an absorption enhancer for lipophilic 
molecules can help on innovative product development capable of delivering the hormone through the 
skin in a consistent manner, improving transdermal therapy of hormonal replacement. MO was dispersed 
in propylene glycol under heat at concentrations of 0% (control), 5% w/w, 10% w/w and 20% w/w. Then, 
0.6% of PG (w/w) was added to each formulation. Permeation profile of the hormone was determined in 
vitro for 48 h using porcine skin in Franz diffusion cells. PG permeation doubled when 5% (w/w) of MO 
was present in formulation in comparison to both the control and higher MO concentrations (10% and 
20% w/w). An equal trend was observed for PG retention in stratum corneum (SC) and reminiscent skin 
(E+D). PG release rates from the MO formulations, investigated using cellulose membranes, revealed that 
concentrations of MO higher than 5% (w/w) hindered PG release, which indeed negatively reflected on 
the hormone permeation through the skin. In conclusion, this work demonstrated the feasibility of MO 
addition (at 5% w/w) in formulations as a simple method to increase transdermal PG delivery for therapies 
of hormonal replacement. In contrast, higher MO concentrations (from 10% to 20% w/w) can control active 
release, and this approach could be extrapolated to other lipophilic, low-molecular-weight molecules.
Uniterms: Monoolein/influence/transdermal therapy. Progesterone/transdermal delivery. Progesterone/
skin retention. Hormonal replacement/transdermal therapy. Skin permeation.
Este trabalho teve como objetivo investigar in vitro a influência de monooleína (MO) na permeação 
transdérmica de progesterona (PG), bem como sobre a retenção cutânea desse hormônio a fim de (i) liberar 
de maneira mais consistente hormônio através da pele para melhorar a terapia transdérmica de reposição 
hormonal e (ii) trazer mais informações sobre o papel da MO como promotor da absorção cutânea de 
moléculas lipofílicas, tema ainda pouco explorado na literatura. MO foi dispersa em propilenoglicol, a 
concentrações de 0% (controle), 5%, 10% e 20% (p/p). Adicionou-se, em seguida, 0,6% (p/p) de PG a 
cada uma das formulações. O perfil de permeação do hormônio foi então determinado in vitro durante 
48 h, utilizando pele de porco em células de difusão do tipo Franz. MO a 5% (p/p) foi capaz de duplicar 
a permeação de PG em comparação ao controle e às concentrações mais elevadas de MO, assim como 
a retenção de PG no estrato córneo (SC) e epiderme e derme remanescentes (E+D). A velocidade de 
liberação de PG a partir das formulações foi investigada usando membranas de celulose e este estudo 
revelou que concentrações de MO superiores a 5% (p/p) impediram a liberacão de PG, o que de fato 
refletiu de forma negativa na permeação cutânea do hormônio. Concluindo, este trabalho demonstrou a 
viabilidade da adição de MO a uma formulação como um método simples para aumentar a permeação 
transdérmica de PG para uso em terapias de reposição hormonal. Por outro lado, altas concentrações 
de MO (de 10% a 20% p/p) controlam a liberação de PG e este efeito pode ser extrapolado para outras 
moléculas lipofílicas de baixa massa molecular.
Uniterms: Monooleína/influência/permeação transdérmica. Progesterona/permeação transdérmica. 
Progesterona/retenção cutânea. Reposição hormonal/terapia transdérmica. Permeação cutânea.
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INTRODUCTION
The use of oral progesterone (PG, Figure 1) is 
approved by the FDA and by other international regulatory 
agencies and is the most conventional strategy for hormone 
replacement therapy in menopausal women (Studd, 2014).
It is undeniable, however, that transdermal delivery 
of PG would be more advantageous than oral therapy, 
if considered the possibility to obtain a controlled 
and prolonged hormone delivery to the blood and the 
avoidance of first-pass metabolism in the liver, which 
guarantee a more consistent bioavailability of the 
hormonal substance (Silva et al., 2010). In addition, 
the painless, non-invasive and easy administration of 
transdermal patches and formulations can improve patient 
acceptance (Martins, Veiga, 2002).
Many papers evaluating transdermal creams and gels 
containing PG for treating menopausal related symptoms 
have been published over the years (Chang et al., 1995; Du 
et al., 2013; Leonetti et al., 2005). However, PG potential 
in preventing estrogen-stimulated cell proliferation has 
not yet been fully explored because current formulations 
and devices are unable to deliver therapeutically relevant 
progesterone concentrations (Zava et al., 2014).
In this context, some research groups have devoted 
their efforts in using many different strategies to overcome 
the stratum corneum (SC) barrier of skin. Swarnakar et 
al. (2007), for instance, prepared and characterized lipid-
based hexosomes for oral administration of PG, but, to 
our knowledge, no further study from the group evaluated 
cutaneous permeation. A more recent study determined 
the efficacy of a transdermal nanostructured formulation 
of PG combined with estriol, and preliminary clinical 
studies demonstrated the system was safe and effective 
(Botelho et al., 2014).
A simpler approach for PG delivery would consist 
on the use of absorption enhancers incorporated in PG 
transdermal formulations. Absorption enhancers reversibly 
decrease skin barrier resistance, allowing the drug to 
penetrating viable tissues to act locally and/or reach the 
systemic circulation (Alexander et al., 2012). Monoolein 
(MO, Figure 2) is one of the most studied absorption 
enhancer (Simonetti et al., 2009; Herai et al., 2007; 
Steluti et al., 2001; Lopes, Collett, Bentley, 2005; Pereira 
et al., 2002; Puglia et al., 2013). It is pharmacologically 
inert, non-toxic, immediate and reversible in action, 
non-irritating, non-allergenic, odorless, colorless and 
chemically and physically compatible with many drugs 
and pharmaceutical excipients (Hadgraft, 1999; Qiu, 
Caffrey, 2000). MO is able to interact with phospholipid 
bilayers of SC lipid matrix and destabilize its structure 
momentarily (Pereira et al., 2002). However, due to 
its high lipophilicity, MO is rarely incorporated in 
formulations containing lipophilic active agents, such as 
PG, since high interaction with the absorption enhancer 
could hinder drug release, hindering drug transdermal 
permeation.
In this way, this work aimed to investigate in vitro 
MO influence on PG transdermal delivery and skin 
retention, which could bring more information about 
the role of MO as absorption enhancer for lipophilic 
molecules, a still little explored matter in scientific 
literature.
MATERIAL AND METHODS
Material
PG was kindly provided by “Farmacotécnica 
Farmácia de Manipulação” (Brasília, Brazil). MO (gliceril 
oleate, ≥ 99%) was purchased from Sigma-Aldrich 
(Steinheim, Germany). Propylene glycol used to prepared 
formulations, as well as to be placed in receptor solution, 
was purchased from Dinâmica Química Ltda. (São Paulo, 
Brazil). Monobasic and dibasic sodium phosphate (Vetec, 
Rio de Janeiro, Brazil), and sodium chloride (Serva, Rio 
de Janeiro, Brazil) were all used in buffer preparation, 
and sodium hydroxide (Dinâmica Química Ltda., São 
Paulo, Brazil) was used to adjust the pHs of the buffer 
and formulations. Regenerated Cellulose Dialysis Tubing 
(Dialysis Tubing MWCO 12000-14000, Fisherbrand) 
used in release studies was purchased from Fisher 
Scientific (Leicestershire, United Kingdom). Methanol 
FIGURE 1 - Chemical structure of progesterone (PG) (MW = 
314.46 g/mol; water solubility = 16.8 mg/L at 25 oC).
FIGURE 2 - Chemical structure of MO (MW = 356.53 g/mol; 
water solubility = 356 µg/L at 25 oC).
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and acetonitrile, used for extraction and chromatographic 
analyses, were of HPLC grade and purchased from Tedia 
Brazil Ltda. (Rio de Janeiro, Brazil). The water used in 
all preparations was of Milli Q grade (Millipore, France). 
Skin
Porcine skin was kindly provided by the Frigorific 
Bonasa (Brasília, Brazil). Porcine ears were obtained 
soon after animal sacrifice, before the scalding process. 
The whole skin was removed from the outer region of the 
ear, separated from its underlying layer with scissors and 
stored frozen at -4 °C for a maximum of 1 month before 
use.
Formulations
Formulations were prepared by adding MO at 5%, 
10% or 20% (w/w) to propylene glycol and heated to 
40 °C for complete homogenization. After cooling, 0.6% 
(w/w) of PG was incorporated to each formulation and 
the pH adjusted to 5 with an aqueous solution of sodium 
hydroxide at 1 M. A control formulation was prepared 
without MO, i.e., simply dissolving 0.6% (w/w) of PG in 
propylene glycol and adjusting the pH to 5.
In vitro skin permeation
Permeation studies were carried out in modified 
“Franz” diffusion cells, mounted with small pieces 
(2 cm × 2 cm) of porcine ear skin separating the donor and 
receptor compartments. The receptor chamber was filled 
with a solution prepared with phosphate buffer (pH 7.4) 
and propylene glycol in the ratio of 60:40 (v/v). The skin 
was hydrated for 30 minutes by adding 1 mL of buffer to 
the donor chamber prior the beginning of the experiments. 
After draw off the buffer, it was added the same volume 
for each of the formulations to be tested or the control 
formulation to the donor compartment, which was closed 
with Parafilm® to minimize formulation evaporation. The 
receptor solution was continuously stirred at 500 rpm for 
48 h. Samples were collected in defined time intervals of 
1 h, 3 h, 6 h, 12 h, 24 h, 30 h, 36 h and 48 h. A minimum 
of four replicates was performed for each formulation.
PG recovery from SC and reminiscent epidermis 
and dermis (E+D)
At the end of each permeation experiment, tape-
stripping technique was performed to determine and 
differentiate PG penetration in SC from that in E+D. The 
skin was removed from the diffusion cell and placed onto 
a flat surface with the SC facing up. That part of skin, 
which had been in contact with the PG donor formulation, 
was cleaned with deionized water (water used to clean 
the skin was discarded). A plastic template with 1.7 cm2 
of exhibition area was placed on the skin in order to leave 
exposed only the drug transport area. Then, the skin was 
tape-stripped 15 times, using Scotch Book Tape (3 M, St 
Paul, Minnesota). PG was determined after extraction of 
the drug from the tapes with methanol over a 12 h period. 
The remaining skin was cut into small pieces and placed 
in plastic tube along with methanol also over a period of 
12 h for drug extraction. The resulting suspensions were 
filtered on 0.22 μm filters and quantified by HPLC.
The PG recovery from SC and E+D was previously 
validated and showed error percentages within the limits 
accepted for validation of methods involving extractive 
processes (± 15%) (FDA, 2000).
In vitro release
These studies were performed using the same 
modified Franz-type diffusion cells, but mounted with 
synthetic hydrophilic membranes of cellulose acetate 
separating the donor and receptor compartments instead 
of skin. The receptor compartment was filled with 15 mL 
of a receptor solution prepared with phosphate buffer (pH 
7.4) and propylene glycol in the ratio of 60:40 (v/v). The 
receptor solution was continuously stirred by means of 
a spinning bar magnet, at 500 rpm. 1 mL of each tested 
formulation was placed on donor compartment and, 
from this time, samples from receptor compartment were 
collected every hour for 12 h. At the end of the experiment, 
the amount of the drug released across the membrane, i.e., 
the amount of PG released in the receptor solution, was 
determined analytically as described below, and release 
kinetics of PG from each MO formulation was determined.
Analytical analysis
PG was quantified by an analytical method using a 
high performance liquid chromatograph (HPLC) Shimadzu 
LC-20 AD, composed by two pumps (model LC 20-AT), 
automatic gun (model 9SIL-20AD) and oven (model CTO 
- 20th century), coupled to a spectrophotometric detector 
(model SPD-M20A) and a computer equipped with the 
chromatographic analysis program Shimadzu LC. A 
reverse-phase column (Dionex 4.0 × 125 mm, 5 µm) was 
used as stationary phase, and mobile phase consisted of a 
mixture of water: acetonitrile (70: 30) (v/v). The mobile 
phase flow rate was 1 mL/min, the sample injection volume 
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was 50 μL, the oven was used at 40 ºC and detection was 
made at 244 nm. The method was validated in terms of 
linearity, precision, accuracy, specificity/selectivity and 
limit of quantification, according to current legislation 
(FDA, 2000).
Data analyses
Three to five replicates of each transport experiment 
were performed. Results are presented as mean ± standard 
deviation (SD) and expressed in terms of the quantity of 
PG per unit area of skin (μg/cm2). Linear regressions were 
obtained with Microsoft Excel 2007. Statistical analyses 
were performed with the program GraphPad Prism. 
Statistical significance was fixed at p < 0.05.
RESULTS AND DISCUSSION
PG is a lipophilic, relatively small and non-charged 
molecule. It presents log P = 3.5, features which are 
generally required for proper SC permeation. However, 
its potency is not high enough to assure high blood 
concentrations for long time periods (Zava et al., 2014). 
This study aimed to investigate the feasibility of MO 
to be used as permeation enhancer in formulations 
incorporating PG for enhancing its transdermal delivery. 
For that, MO was dispersed in propylene glycol in three 
different concentrations and PG permeation from these 
formulations were evaluated relatively to a control 
(without MO addition).
Figure 3 shows PG in vitro permeation profiles for 
48 h as a function of MO concentration in the formulations.
Although PG does permeate the skin passively, 
permeated levels up to the first 24 h of experiment were 
under method’s limit of quantification (LOQ = 500 ng/
mL). Even until 36 h, PG levels were near the LOQ for 
control formulation and formulations with 10% and 20% 
of MO. 
It is clear from Figure 3 that 5% (w/w) of MO in 
formulation was sufficient to increase in approximately 
2-fold PG permeation when compared to control. Pereira 
et al. (2002) studied transdermal delivery of PG from MO 
dispersed in mineral oil (at 20%) and observed a 3-fold 
enhance in PG delivery over control (240 and 80 µg/cm2, 
respectively, after 48 h of experiment). However, authors 
used mice skin as a model, whose SC is much thinner than 
porcine and human skin, compromising the comparison 
with the data presented in this paper.
Despite of the increase in PG permeation provided 
by 5% (w/w) MO in formulation, 20% (w/w) of MO 
dramatically decreased (in about 50%) PG permeation 
through porcine skin (P > 0.05). Steluti et al. (2001) 
observed an increase in permeation of aminolevulinic 
acid (ALA) through mouse skin from all formulations 
containing the same range of MO concentrations (5%, 
10%, and 20%), while Simonetti et al. (2009), evaluating 
the effect MO on cisplatin (CIS) permeation, showed 
an increase in drug flux with the increase, up to 10%, of 
the enhancer. It is interesting to notice that, as molecule 
hydrosolubility decreases, (ALA>CIS>PG), a progressive 
annulment of MO enhancement effect is observed. A 
possible reason for this is that high MO concentrations 
increase formulation lipophilicity, hindering drug release.
To test the above-mentioned hypothesis, release 
profile of PG from MO formulations was assessed using 
cellulose membrane, and the results are presented in 
Figure 4.
As expected, only 5% (w/w) of MO in the formulation 
did not increase lipophilicity highly enough to influence 
PG release in comparison with control (P > 0.05). Instead, 
MO at 10% or 20% (w/w) hindered the hormone release 
(P < 0.05). As it can be seen in Figure 3, this effect had 
a significant influence on the permeation of PG through 
the skin.
The data presented in Table I shows clearer that MO 
at 5% (w/w) was not able to influence PG release kinetics, 
while at 10% and 20% (w/w) decreased by 2 and 2.5-fold 
the hormone release flux.
FIGURE 3 - PG permeation profile through porcine skin from 
formulations containing 0% w/w (Control) (■), 5% w/w (●), 
10% w/w (▲) and 20% w/w (×) of MO. Each point represents 
the average value for 4-5 determinations and the vertical bars 
represent the standard deviation (± SD).
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TABLE I - PG release flux (µg/cm2/h) from the formulations 
containing 0% (control), 5% MO, 10% MO and 20% of MO
Formulation Release flux 
(μg/cm2/h)
Correlation 
coefficient (r)*
Control 28.2 ± 5.0 0.992
5% MO 27.4 ± 2.7 0.997
10% MO 15.0 ± 1.2 0.993
20% MO 11.1 ± 2.0 0.989
*all formulations release PG in a zero order kinetics.
FIGURE 4 - PG release profiles of the PG in propylene glycol 
formulations (0.6% m/m) containing different concentrations 
of MO: Control (■); 5% (●), 10% (▲) and 20% (×). Each point 
represents the average of 4 experiments and the vertical bars 
represent the standard deviation of the mean (± SD).
Similar to our results, Herai et al. (2007) observed 
that the addition of 5% (w/w) of MO in formulation did not 
alter significantly the release rate of the chemotherapeutic 
agent, doxorubicin, while higher MO concentrations 
did. Herai et al. attributed this effect to an increase in 
lipophilicity or viscosity provided by MO in the vehicle 
(Herai et al., 2007). Taken the data together, the effect 
of lipophilicity provided by MO must be much more 
pronounced than any viscosity increment it could 
provide to the formulation, since Simonetti et al. (2009) 
demonstrated that the addition of MO did not alter release 
rate of the more hydrophilic CIS, in any concentration it 
was tested.
Figure 5 summarizes the data of PG recovered from 
SC, E+D and receptor solution after 48 h of skin treatment 
with formulations containing 0%, 5%, 10% or 20% (w/w) 
of MO.
FIGURE 5 - PG recovered from the SC, reminiscent E+D and 
receptor solution after 48 h of treatment with formulations 
containing MO at different concentrations. Bars represent the 
average of 4-5 experiments and vertical bars represent the 
standard deviation of the mean (± SD). *Significant difference 
from control in SC samples (P < 0.05); #Significant difference 
from control in E + D samples (P < 0.05); $Significant difference 
from control in receptor samples (P < 0.05).
The formulation containing 5% MO (w/w) not 
only doubled the PG amount permeated, as it also 
increased hormone retention in reminiscent skin (E + 
D). Interestingly, 10% of MO (w/w), even restricting PG 
release, was still capable of retaining a great amount of 
PG in E + D, even though this high skin retention was not 
able to guarantee higher transdermal flux of the hormone.
CONCLUSION
In conclusion, the data presented in this work 
demonstrated the feasibility of MO addition as a simple 
method to increase transdermal delivery of PG for the 
therapy of hormonal replacement. It was shown that, 
depending on the concentration added to the topical and 
transdermal formulation, MO could cause opposite effects, 
i.e., while small concentration of MO (5% w/w) can 
enhance about 2-fold transdermal delivery of the lipophilic 
molecule, higher concentrations (from 10% to 20% w/w) 
of MO significantly reduces PG skin permeation as a result 
of a more pronounced controlling effect in drug release. 
Such conclusion is corroborated by the 2-fold reduction in 
PG release observed at higher MO concentrations.
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